RDY — Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited (RDY) Q3 FY '26 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: INR 8,727 crores (~USD 971 million), up 4.4% YoY but down 0.9% sequentially.
• EBITDA: INR 2,049 crores (~USD 228 million), down 11% YoY and 13% sequentially; EBITDA margin at 23.5%, adjusted for a one-time provision related to new labor laws, the margin was 24.8%.
• Net Profit: INR 1,210 crores (~USD 135 million), down 14% YoY and 16% sequentially; diluted EPS of INR 14.52.
• Gross Profit Margin: 53.6%, a decrease of 505 basis points YoY due to lower Lenalidomide sales and pricing pressures.
• SG&A Expenses: INR 2,692 crores (~USD 300 million), up 12% YoY; accounted for 31% of revenue.
• R&D Spend: INR 615 crores (~USD 68 million), down 8% YoY; 7% of revenues.
• Net Cash Surplus: INR 3,069 crores (~USD 342 million).

2. Strategic Updates and Business Highlights

• Growth Drivers: Strong performance in branded businesses, particularly in India and emerging markets, with double-digit growth excluding Lenalidomide.
• New Collaborations: Entered a strategic partnership with Immutep for an oncology drug, Eftilagimod Alfa, with potential milestones of up to $350 million.
• Product Launches: Launched Hevaxin, a Hepatitis-E vaccine, and received marketing authorization for semaglutide injection in India.
• Integration Progress: The acquired Nicotine Replacement Therapy (NRT) business is progressing well, with 85% operational control achieved.
• Regulatory Updates: Received approvals for denosumab biosimilar in Europe; however, faced a complete response letter (CRL) from the USFDA for the same product.

3. Forward Guidance and Outlook

• India Business: Expected growth to remain robust, with guidance of 15%+ growth for FY '27, driven by innovative products and acquisitions.
• Semaglutide Launch: Anticipated launch in Canada between February and May 2026, with India launch planned for March 2026.
• Biosimilars: Continued focus on launching biosimilars, with abatacept expected to launch in Europe by July 2027.
• SG&A Management: Expecting moderation in SG&A growth, with a focus on cost containment.

4. Bad News, Challenges, or Points of Concern

• Lenalidomide Sales Decline: Significant decline in sales impacted overall revenue and margins, with expectations of zero sales going forward.
• Pricing Pressure: Continued pricing erosion in U.S. and European generics markets.
• Regulatory Risks: Ongoing scrutiny and potential delays related to approvals for biosimilars, particularly denosumab and rituximab.
• Margin Compression: Gross margins expected to decline further, projected in the range of 50% to 55% without Lenalidomide sales.

5. Notable Q&A Insights

• India Growth Breakdown: Organic growth in India, excluding acquisitions, estimated between 17% and 18%.
• Semaglutide Pricing: Competitive pricing expected in Canada, with a range of $20 to $70 per unit anticipated.
• Biosimilar Timeline: Uncertainty regarding timelines for denosumab and rituximab approvals, with potential delays of 6 months or more.
• NRT Business: Growth in NRT business driven by favorable currency impacts, with expectations of steady single-digit growth moving forward.
• Market Dynamics: Erez Israeli emphasized the importance of strategic partnerships and innovation to maintain competitive advantage in a challenging market.

This summary encapsulates the key aspects of Dr. Reddy's Q3 FY '26 earnings call, highlighting both the positive developments and the challenges faced by the company.